Opus Genetics (NASDAQ:IRD - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.
Several other brokerages also recently issued reports on IRD. Jones Trading decreased their price target on Opus Genetics from $9.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Craig Hallum initiated coverage on Opus Genetics in a research note on Friday, April 11th. They issued a "buy" rating and a $6.00 price objective for the company. Finally, HC Wainwright restated a "buy" rating and issued a $8.00 price objective on shares of Opus Genetics in a research note on Friday, June 27th.
Get Our Latest Stock Report on Opus Genetics
Opus Genetics Stock Performance
Shares of NASDAQ:IRD traded down $0.01 during midday trading on Friday, hitting $1.11. 87,599 shares of the stock were exchanged, compared to its average volume of 512,935. The stock has a market capitalization of $65.92 million, a price-to-earnings ratio of -0.52 and a beta of -0.02. The business's 50-day moving average price is $1.00 and its 200 day moving average price is $1.02. Opus Genetics has a 12 month low of $0.65 and a 12 month high of $1.75.
Opus Genetics (NASDAQ:IRD - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.02. Opus Genetics had a negative return on equity of 283.28% and a negative net margin of 429.42%. The firm had revenue of $4.30 million for the quarter, compared to analyst estimates of $4.00 million. As a group, sell-side analysts expect that Opus Genetics will post -1.22 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in Opus Genetics in the 1st quarter worth about $26,000. Apollon Wealth Management LLC bought a new position in Opus Genetics in the 1st quarter worth about $28,000. Comerica Bank bought a new position in Opus Genetics in the 1st quarter worth about $29,000. Kestra Private Wealth Services LLC bought a new position in Opus Genetics in the 1st quarter worth about $47,000. Finally, Voss Capital LP bought a new position in Opus Genetics in the 1st quarter worth about $147,000. Institutional investors own 14.97% of the company's stock.
Opus Genetics Company Profile
(
Get Free Report)
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Featured Stories
Before you consider Opus Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opus Genetics wasn't on the list.
While Opus Genetics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
